Complete financial analysis of BINEX Co., Ltd. (053030.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BINEX Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- PT Mahaka Media Tbk (ABBA.JK) Income Statement Analysis – Financial Results
- Recharge Resources Ltd. (RECHF) Income Statement Analysis – Financial Results
- Yokohama Maruuo Co., Ltd. (8045.T) Income Statement Analysis – Financial Results
- Hawaiian Electric Company, Inc. PFD J 4.75% (HAWLI) Income Statement Analysis – Financial Results
- Infinity Logistics and Transport Ventures Limited (1442.HK) Income Statement Analysis – Financial Results
BINEX Co., Ltd. (053030.KQ)
About BINEX Co., Ltd.
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; vitamins and nutrients; antihistamine products; antivertigo products; and OTC products. BINEX Co., Ltd. has a co-development partnership with Genexine, Inc. to develop COVID-19 vaccine. The company was founded in 1957 and is based in Incheon, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 154.82B | 156.68B | 134.40B | 132.98B | 125.26B | 104.04B | 78.03B | 80.92B | 71.14B | 57.30B | 55.13B |
| Cost of Revenue | 98.17B | 86.46B | 75.00B | 70.63B | 69.23B | 56.47B | 50.36B | 52.61B | 38.84B | 39.05B | 30.28B |
| Gross Profit | 56.66B | 70.21B | 59.40B | 62.34B | 56.03B | 47.57B | 27.67B | 28.32B | 32.29B | 18.25B | 24.85B |
| Gross Profit Ratio | 36.59% | 44.81% | 44.19% | 46.88% | 44.73% | 45.72% | 35.46% | 34.99% | 45.40% | 31.85% | 45.08% |
| Research & Development | 1.31B | 1.62B | 384.00M | 1.10B | 1.04B | 894.57M | 622.05M | 817.80M | 1.17B | 2.18B | 1.64B |
| General & Administrative | 17.02B | 4.19B | 3.89B | 3.70B | 14.42B | 13.80B | 13.08B | 12.41B | 12.76B | 12.23B | 12.33B |
| Selling & Marketing | 36.79B | 33.85B | 29.98B | 30.01B | 28.76B | 25.49B | 21.34B | 16.64B | 11.57B | 8.61B | 9.33B |
| SG&A | 53.86B | 50.93B | 45.98B | 44.67B | 43.25B | 39.44B | 34.54B | 29.20B | 24.43B | 20.83B | 21.67B |
| Other Expenses | 0.00 | -485.47M | -423.68M | -440.20M | -460.02M | -392.79M | -334.09M | -283.30M | -362.32M | 0.00 | 0.00 |
| Operating Expenses | 55.12B | 53.03B | 46.78B | 46.20B | 44.75B | 40.72B | 35.50B | 30.30B | 25.97B | 22.66B | 30.57B |
| Cost & Expenses | 153.04B | 139.50B | 121.79B | 116.84B | 113.98B | 97.19B | 85.86B | 82.91B | 64.81B | 61.71B | 60.85B |
| Interest Income | 688.66M | 824.31M | 486.91M | 337.38M | 360.21M | 1.42B | 1.51B | 1.39B | 201.71M | 1.02B | 2.01B |
| Interest Expense | 0.00 | 2.06B | 1.69B | 1.44B | 2.10B | 2.04B | 1.93B | 1.84B | 1.22B | 1.54B | 2.73B |
| Depreciation & Amortization | 9.89B | 8.30B | 6.00B | 5.68B | 9.06B | 8.98B | 8.98B | 8.08B | 6.34B | 5.95B | 3.88B |
| EBITDA | 15.85B | 25.60B | 30.93B | 13.19B | 21.72B | 15.83B | -835.54M | 6.22B | 5.17B | 1.61B | 4.08B |
| EBITDA Ratio | 10.24% | 16.26% | 13.85% | 16.41% | 16.24% | 15.22% | 1.48% | 7.53% | 17.81% | -0.52% | 7.39% |
| Operating Income | 1.78B | 17.18B | 12.61B | 16.14B | 11.28B | 6.85B | -7.83B | -1.99B | 6.33B | -6.25B | 196.24M |
| Operating Income Ratio | 1.15% | 10.96% | 9.38% | 12.14% | 9.00% | 6.58% | -10.03% | -2.46% | 8.90% | -10.90% | 0.36% |
| Total Other Income/Expenses | 3.11B | -1.95B | 11.62B | -9.93B | -657.55M | -2.05B | -3.92B | -1.72B | -8.46B | -1.32B | -7.93B |
| Income Before Tax | 4.89B | 15.23B | 23.24B | 6.08B | 10.57B | 4.80B | -11.75B | -3.70B | -2.39B | -5.43B | -7.73B |
| Income Before Tax Ratio | 3.16% | 9.72% | 17.29% | 4.57% | 8.44% | 4.61% | -15.06% | -4.58% | -3.36% | -9.48% | -14.02% |
| Income Tax Expense | 311.13M | 2.87B | 5.20B | -143.89M | 2.24B | -1.39B | -731.19M | -621.43M | 4.95B | 1.25B | 31.50M |
| Net Income | 4.67B | 12.44B | 19.09B | 6.41B | 8.50B | 6.34B | -11.29B | -3.00B | -6.81B | -4.07B | -7.44B |
| Net Income Ratio | 3.02% | 7.94% | 14.21% | 4.82% | 6.79% | 6.09% | -14.48% | -3.71% | -9.58% | -7.10% | -13.50% |
| EPS | 151.04 | 402.42 | 613.78 | 205.58 | 272.69 | 203.86 | -367.27 | -97.69 | -231.64 | -170.01 | -346.00 |
| EPS Diluted | 143.73 | 402.42 | 613.78 | 205.58 | 272.69 | 203.86 | -367.27 | -97.69 | -231.64 | -170.01 | -346.00 |
| Weighted Avg Shares Out | 30.92M | 30.92M | 31.11M | 31.19M | 31.19M | 31.09M | 30.75M | 30.76M | 29.41M | 23.93M | 21.52M |
| Weighted Avg Shares Out (Dil) | 32.50M | 30.92M | 31.11M | 31.19M | 31.19M | 31.09M | 30.75M | 30.76M | 29.41M | 23.93M | 21.52M |
Source: https://incomestatements.info
Category: Stock Reports